AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 1.17
(0.0%)
SEK 1.17
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -38.26 Million SEK | 32.21% |
| 2022 | -56.44 Million SEK | 27.57% |
| 2021 | -77.92 Million SEK | -8.87% |
| 2020 | -71.57 Million SEK | -40.6% |
| 2019 | -50.9 Million SEK | -41.83% |
| 2018 | -35.89 Million SEK | -233.36% |
| 2017 | -10.76 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -8.85 Million SEK | 12.32% |
| 2024 Q1 | -9.99 Million SEK | 0.41% |
| 2023 Q4 | -10.03 Million SEK | -25.98% |
| 2023 FY | -38.3 Million SEK | 32.13% |
| 2023 Q3 | -7.96 Million SEK | 24.08% |
| 2023 Q2 | -10.49 Million SEK | -7.53% |
| 2023 Q1 | -9.76 Million SEK | 11.5% |
| 2022 FY | -56.44 Million SEK | 27.57% |
| 2022 Q3 | -11.17 Million SEK | 48.22% |
| 2022 Q2 | -21.57 Million SEK | -70.33% |
| 2022 Q1 | -12.66 Million SEK | 44.08% |
| 2022 Q4 | -11.03 Million SEK | 1.27% |
| 2021 Q2 | -15.73 Million SEK | 31.62% |
| 2021 FY | -77.92 Million SEK | -8.87% |
| 2021 Q1 | -23 Million SEK | -29.48% |
| 2021 Q4 | -22.64 Million SEK | -36.92% |
| 2021 Q3 | -16.54 Million SEK | -5.16% |
| 2020 Q1 | -13.85 Million SEK | 11.69% |
| 2020 Q2 | -18.45 Million SEK | -33.26% |
| 2020 FY | -71.57 Million SEK | -40.6% |
| 2020 Q4 | -17.76 Million SEK | 17.37% |
| 2020 Q3 | -21.5 Million SEK | -16.5% |
| 2019 FY | -50.9 Million SEK | -41.83% |
| 2019 Q4 | -15.68 Million SEK | -16.83% |
| 2019 Q3 | -13.42 Million SEK | -30.26% |
| 2019 Q2 | -10.3 Million SEK | 10.3% |
| 2019 Q1 | -11.49 Million SEK | 10.77% |
| 2018 Q1 | -9.62 Million SEK | -69.8% |
| 2018 FY | -35.89 Million SEK | -233.36% |
| 2018 Q4 | -12.87 Million SEK | -127.11% |
| 2018 Q3 | -5.67 Million SEK | 26.57% |
| 2018 Q2 | -7.72 Million SEK | 19.76% |
| 2017 Q3 | -5 Million SEK | 0.0% |
| 2017 Q4 | -5.66 Million SEK | -13.29% |
| 2017 FY | -10.76 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | -188.792% |
| BioGaia AB (publ) | 440.9 Million SEK | 108.678% |
| Enzymatica AB (publ) | -48.06 Million SEK | 20.39% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 8.547% |
| Gabather AB (publ) | -9.47 Million SEK | -303.863% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | -160.64% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | -39.322% |
| Nanexa AB (publ) | -76.62 Million SEK | 50.066% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | -171.786% |
| ODI Pharma AB | -1.34 Million SEK | -2751.883% |
| Orexo AB (publ) | -109.5 Million SEK | 65.058% |
| Probi AB (publ) | 11.32 Million SEK | 438.004% |
| Swedencare AB (publ) | 173.2 Million SEK | 122.091% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 100.822% |
| Toleranzia AB | -7.89 Million SEK | -384.882% |
| Vivesto AB | -356.71 Million SEK | 89.274% |